Genetic analyses have shown the presence of unbalanced chromosome 17q gain in 90% of high-risk neuroblastomas, and high expression of PPM1D is associated with adverse patient outcome [8,12,13,14,34]. The gene discussed is PPM1D; the disease is neuroblastoma.